Dr Ryman is a neurologist and geneticist by training, and joined Aeovian in November 2022 as Chief Medical Officer. Prior to joining, he was most recently Chief Medical Officer of Levo Therapeutics, where he led clinical development of LV-101 (intranasal carbetocin) and other pipeline programs for treatment of Prader-Willi syndrome through the acquisition of Levo in 2022.

 

Previously to this, he was Executive Medical Director at AveXis, the first company to successfully develop an AAV9 gene replacement therapy for spinal muscular atrophy, leading to its acquisition by Novartis. Before AveXis, he worked at AbbVie on a variety of drug development programs in neurological disorders, including contributions to the successful development of Duopa (carbidopa/levodopa enteral suspension) and ABBV-951 (foslevodopa/foscarbidopa subcutaneous infusion).

 

Before joining AbbVie, he worked at the Dominantly Inherited Alzheimer Disease Trials Unit (DIAN-TU), a global clinical trial in genetic early-onset Alzheimer disease conducted with funding from the DIAN Pharma Consortium. Prior to his medical training, he additionally worked on a variety of preclinical and translational research programs at the Lawrence Berkeley National Laboratory, CLONTECH Laboratories, and Becton Dickinson Biosciences.

 

He holds an M.D. and Ph.D. in Human and Molecular Genetics from the Case Western Reserve University School of Medicine Medical Scientist Training Program, and a B.S. in Molecular and Cell Biology from the University of California at Berkeley.